| Identification | Back Directory | [Name]
Chloroquine-d5 (phosphate) | [CAS]
1854126-42-3 | [Synonyms]
Chloroquine-d5 (phosphate)
Hydroxychloroquine D5 Diphosphate | [Molecular Formula]
C18H29ClN3O4P | [MOL File]
1854126-42-3.mol | [Molecular Weight]
417.87 |
| Hazard Information | Back Directory | [Description]
Chloroquine-d5 is intended for use as an internal standard for the quantification of chloroquine by GC- or LC-MS. Chloroquine is an aminoquinoline that is an inhibitor of autophagy and has antimalarial, anti-inflammatory, anticancer, and antiviral activities.1,2,3,4,5 Chloroquine inhibits autophagosome-lysosome fusion in HeLa cells when used at a concentration of 100 μM.1 It is active against the chloroquine-sensitive GC03 strain of P. falciparum (IC50 = 29.2 nM) but has decreased activity against mutant pfcrt P. falciparum (IC50s = 100-150 nM).3 Chloroquine prevents infection by severe acute respiratory coronavirus 2 (SARS-CoV-2) in Vero cells (EC50 = 1.13 μM) but does not inhibit SARS-CoV replication in the lungs in a mouse model of SARS-CoV infection.5,6 It inhibits the growth of human SSC25 and CAL 27 oral squamous cell carcinoma cells (IC50s = 29.9 and 17.3 μM, respectively), as well as A498, SN12C, RXF 393, and 769-P renal cancer cells (IC50s = 16, 62, 81, and 25 μM, respectively).4,7 It reduces tumor growth in a CAL 27 mouse xenograft model and a 4T1 mouse allograft model when administered at a dose of 50 mg/kg.4,8 Formulations containing chloroquine have been used in the prevention of malaria, as well as the treatment of rheumatoid arthritis and systemic lupus erythematosus (SLE), and have been associated with cardiotoxicity and myopathy. | [References]
1. Mauthe, M., Orhon, I., Rocchi, C., et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion Autophagy 14(8),1435-1455(2018).
2. Plantone, D., and Koudriavtseva, T. Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: A mini-review Clin. Drug Investig. 38(8),653-671(2018).
3. Sidhu, A.B.S., Verdier-Pinard, D., and Fidock, D.A. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations Science 298(5591),210-213(2002).
4. Jia, L., Wang, J., Wu, T., et al. In vitro and in vivo antitumor effects of chloroquine on oral squamous cell carcinoma Mol. Med. Rep. 16(5),5779-5786(2017).
5. Wang, M., Cao, R., Zhang, L., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Cell Res. 30(3),269-271(2020).
6. Barnard, D.L., Day, C.W., Bailey, K., et al. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice Antivir. Chem. Chemother. 17(5),275-784(2006).
7. Grimaldi, A., Santini, D., Zappavigna, S., et al. Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells Cancer Biol. Ther. 16(4),567-579(2015).
8. Jiang, P.-D., Zhao, Y.-L., Deng, X.-Q., et al. Antitumor and antimetastatic activities of chloroquine diphosphate in a murine model of breast cancer Biomed. Pharmacother. 64(9),609-614(2010). |
|
|